

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
)	
Stephen Mark McAllister)	Group Art Unit: 1615
)	
Application No.: 10/565,462)	Examiner: TRAN, SUSAN T
)	
Filed: January 20, 2006)	
)	Confirmation No.: 9920
For: Pharmaceutical formulations)	
)	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

**REVOCATION OF POWER OF ATTORNEY
STATEMENT UNDER 37 C.F.R. § 3.73(b)
AND GRANT OF NEW POWER OF ATTORNEY**

The undersigned, a representative authorized to sign on behalf of the assignee owning all of the interest in this patent application, hereby revokes all previous powers of attorney or authorization of agent granted in this application before the date of execution hereof.

As required by 37 C.F.R. § 3.73(b), the undersigned verifies that Capsugel Belgium BVBA is the assignee of the entire right, title, and interest in the patent application identified above by virtue of an assignment from the inventors to Smithkline Beecham PLC recorded in the U.S. Patent and Trademark Office at Reel 017333, Frame 0178, a change of name from Smithkline Beecham PLC to Smithkline Beecham Limited recorded in the U.S. Patent and Trademark Office at Reel 025113, Frame 0549, an assignment from Smithkline Beecham Limited to Pfizer, Inc. recorded in the U.S.

Application No.: 10/565,462
Attorney Docket No.: 11795.0031

Patent and Trademark Office at Reel 025833, Frame 0373 and an assignment from Pfizer, Inc. to Capsugel Belgium BVBA recorded in the U.S. Patent and Trademark Office at Reel 026798, Frame 0043.

The undersigned representative of the Assignee hereby grants its power of attorney to the patent practitioners associated with **FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.**, Customer Number 22,852, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and to receive the Letters Patent.

Please send all future correspondence concerning this application to Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P., Customer No. 22,852.

Dated:

October 12, 2011.

By: _____



Carl Mourisse
Managing Director
Capsugel Belgium BVBA